Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pai, Sachin
ROSELLA, NCT05257408 / 2022-000662-18: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer	Active, not recruiting	3	360	Europe, Canada, US, RoW	Nab-paclitaxel 80 mg/m^2, Relacorilant 150 mg once daily (QD), Nab-paclitaxel 100 mg/m^2	Corcept Therapeutics, Gynecologic Oncology Group	Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms	12/24	12/25
Lung-Map Screening Study, NCT03851445: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer	Recruiting	2/3	10000	US	Screening Platform	SWOG Cancer Research Network, National Cancer Institute (NCI)	Previously Treated Non-Small Cell Lung Cancer	01/29	01/29
NCT05222802: A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)	Active, not recruiting	1	52	US	ERAS-801	Erasca, Inc.	Glioblastoma Multiforme	01/25	09/25